Kinase Inhibition - A New Approach to the Treatment of Rheumatoid Arthritis

被引:21
作者
Fox, David A. [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA
关键词
JAK INHIBITOR; TOFACITINIB; CP-690,550; PLACEBO; TRIAL;
D O I
10.1056/NEJMe1206315
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:565 / 567
页数:3
相关论文
共 15 条
[1]
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].
Changelian, PS ;
Flanagan, ME ;
Ball, DJ ;
Kent, CR ;
Magnuson, KS ;
Martin, WH ;
Rizzuti, BJ ;
Sawyer, PS ;
Perry, BD ;
Brissette, WH ;
McCurdy, SP ;
Kudlacz, EM ;
Conklyn, MJ ;
Elliott, EA ;
Koslov, ER ;
Fisher, MB ;
Strelevitz, TJ ;
Yoon, K ;
Whipple, DA ;
Sun, JM ;
Munchhof, MJ ;
Doty, JL ;
Casavant, JM ;
Blumenkopf, TA ;
Hines, M ;
Brown, MF ;
Lillie, BM ;
Subramanyam, C ;
Shang-Poa, C ;
Milici, AJ ;
Beckius, GE ;
Moyer, JD ;
Su, CY ;
Woodworth, TG ;
Gaweco, AS ;
Beals, CR ;
Littman, BH ;
Fisher, DA ;
Smith, JF ;
Zagouras, P ;
Magna, HA ;
Saltarelli, MJ ;
Johnson, KS ;
Nelms, LF ;
Des Etages, SG ;
Hayes, LS ;
Kawabata, TT ;
Finco-Kent, D ;
Baker, DL ;
Larson, M .
SCIENCE, 2003, 302 (5646) :875-878
[2]
Sensitivity and Resistance to Regulation by IL-4 during Th17 Maturation [J].
Cooney, Laura A. ;
Towery, Keara ;
Endres, Judith ;
Fox, David A. .
JOURNAL OF IMMUNOLOGY, 2011, 187 (09) :4440-4450
[3]
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis [J].
Fleischmann, Roy ;
Kremer, Joel ;
Cush, John ;
Schulze-Koops, Hendrik ;
Connell, Carol A. ;
Bradley, John D. ;
Gruben, David ;
Wallenstein, Gene V. ;
Zwillich, Samuel H. ;
Kanik, Keith S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :495-507
[4]
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) [J].
Ghoreschi, Kamran ;
Jesson, Michael I. ;
Li, Xiong ;
Lee, Jamie L. ;
Ghosh, Sarbani ;
Alsup, Jason W. ;
Warner, James D. ;
Tanaka, Masao ;
Steward-Tharp, Scott M. ;
Gadina, Massimo ;
Thomas, Craig J. ;
Minnerly, John C. ;
Storer, Chad E. ;
LaBranche, Timothy P. ;
Radi, Zaher A. ;
Dowty, Martin E. ;
Head, Richard D. ;
Meyer, Debra M. ;
Kishore, Nandini ;
O'Shea, John J. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (07) :4234-4243
[5]
Kontzias Apostolos, 2012, F1000 Med Rep, V4, P5, DOI 10.3410/M4-5
[6]
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo (vol 60, pg 1895, 2009) [J].
Kremer, Joel M. ;
Bloom, Bradley J. ;
Breedveld, Ferdinand C. ;
Coombs, John H. ;
Fletcher, Mark P. ;
Gruben, David ;
Krishnaswami, Sriram ;
Burgos-Vargas, Ruben ;
Wilkinson, Bethanie ;
Zerbini, Cristiano A. F. ;
Zwillich, Samuel H. .
ARTHRITIS AND RHEUMATISM, 2012, 64 (05) :1487-1487
[7]
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo [J].
Kremer, Joel M. ;
Bloom, Bradley J. ;
Breedveld, Ferdinand C. ;
Coombs, John H. ;
Fletcher, Mark P. ;
Gruben, David ;
Krishnaswami, Sriram ;
Burgos-Vargas, Ruben ;
Wilkinson, Bethanie ;
Zerbini, Cristiano A. F. ;
Zwillich, Samuel H. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (07) :1895-1905
[8]
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis [J].
Milici, Anthony J. ;
Kudlacz, Elizabeth M. ;
Audoly, Laurent ;
Zwillich, Samuel ;
Changelian, Paul .
ARTHRITIS RESEARCH & THERAPY, 2008, 10 (01)
[9]
Jak3 and the pathogenesis of severe combined immunodeficiency [J].
O'Shea, JJ ;
Husa, M ;
Li, D ;
Hofmann, SR ;
Watford, W ;
Roberts, JL ;
Buckley, RH ;
Changelian, P ;
Candotti, F .
MOLECULAR IMMUNOLOGY, 2004, 41 (6-7) :727-737
[10]
A new modality for immunosuppression: Targeting the JAK/STAT pathway [J].
O'Shea, JJ ;
Pesu, M ;
Borie, DC ;
Changelian, PS .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (07) :555-564